DaVita (NYSE:DVA) Trading Down 5.3% – What’s Next?

Posted by Francis Steltz on Sep 19th, 2026

Shares of DaVita Inc. (NYSE:DVA – Get Free Report) fell 5.3% during trading on Thursday . The company traded as low as $184.18 and last traded at $183.4890. 621,564 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 917,575 shares. The stock had previously closed at $193.86.

Analyst Upgrades and Downgrades

DVA has been the subject of a number of research reports. Oppenheimer set a $220.00 price target on DaVita in a report on Friday, August 7th. Raymond James Financial set a $220.00 target price on DaVita in a report on Friday, August 7th. Weiss Ratings upgraded DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 5th. TD Cowen upgraded shares of DaVita from a “hold” rating to a “buy” rating and increased their target price for the stock from $201.00 to $220.00 in a report on Friday, August 7th. Finally, UBS Group upped their price target on shares of DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, DaVita presently has an average rating of “Moderate Buy” and a consensus price target of $233.43.

View Our Latest Research Report on DaVita

DaVita Stock Up 0.3%

The company has a market capitalization of $11.71 billion, a PE ratio of 15.02, a PEG ratio of 0.47 and a beta of 0.83. The business has a 50 day simple moving average of $199.60 and a 200 day simple moving average of $186.70.

DaVita (NYSE:DVA – Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 EPS for the quarter, topping the consensus estimate of $3.88 by $0.14. The business had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities analysts expect that DaVita Inc. will post 14.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Value Investment Professionals LLC lifted its stake in shares of DaVita by 2.0% in the 2nd quarter. Value Investment Professionals LLC now owns 2,501 shares of the company’s stock valued at $556,000 after purchasing an additional 50 shares during the period. Kesler Norman & Wride LLC lifted its position in shares of DaVita by 0.8% during the 1st quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company’s stock valued at $1,048,000 after buying an additional 55 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in DaVita by 4.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company’s stock worth $426,000 after acquiring an additional 76 shares during the period. Root Financial Partners LLC increased its stake in shares of DaVita by 128.0% during the first quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares in the last quarter. Finally, IFP Advisors Inc lifted its position in shares of DaVita by 32.4% in the second quarter. IFP Advisors Inc now owns 437 shares of the company’s stock valued at $97,000 after acquiring an additional 107 shares in the last quarter. 90.12% of the stock is currently owned by hedge funds and other institutional investors.

DaVita Company Profile

(Get Free Report)

DaVita Inc (NYSE: DVA) is a healthcare company focused primarily on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis services for people with chronic kidney failure, including in-center hemodialysis and home-based dialysis options. Its services also include clinical care, education, nutrition support and other resources intended to help patients manage kidney disease.

DaVita also provides broader kidney-care services, including chronic kidney disease management, care coordination and support for patients who may be candidates for kidney transplantation.